Over $3 Billion in BD Deals: Five Major Transactions in One Day as BI, BMS, and Other MNCs Make Strategic Moves

On April 22, 2024, as major pharmaceutical companies successively disclosed their Q1 financial reports, BD transactions appeared intensively. According to incomplete statistics, only on the 22nd, five deals were announced, with a total amount far exceeding 3 billion US dollars.

On April 22, BI collaborated with the British company Ochre Bio. The former discovered multiple novel liver regeneration targets based on the latter’s AI technology platform (which generates extensive spatial genomics data from donor livers).

According to the agreement, Ochre Bio will receive an upfront payment and near-term payments totaling $35 million, followed by milestone payments and sales royalties, with the total transaction value exceeding $1 billion.

When the company secured $30 million in Series A financing in 2022, it announced that all funds would be dedicated to developing RNA therapies for chronic liver disease.

Interestingly, as early as January 3 this year,BI Announces a Deal Totaling Over $2 Billion withRibo Biotech reached a cooperation, both parties will jointly develop treatmentsNASH/MASHSmall Nucleic Acid Innovative Therapy.

On April 22, BMS and Cellares reached a global capacity reservation and supply agreement for the production of CAR-T therapies, with a total transaction value of $380 million.

Cellares as a company dedicatedAn Integrated Development and Manufacturing Organization (IDMO) for clinical and industrial-scale cell therapy manufacturing reduces costs and increases efficiency for CAR-T therapies by combining integrated automation with high-throughput platforms, and BMS is one of the company's investors.

In 2023, BMS's two marketed CAR-T products (Abecma, Breyanzi) generated revenues of $472 million (+22%) and $364 million (100%), respectively, totaling $836 million.

In addition, in April this year, Breyanzi received FDA accelerated approval for a new indication: relapsed or refractory CLL/SLL patients who have been treated with a BTK inhibitor and a BCL-2 inhibitor.

April 22,Ipsen andSkyhawk Announces RNA Therapeutics Collaboration in Rare CNS Disorders

Ipsen will have the right to opt for global exclusive rights to two candidate products and assume responsibility for further development and commercialization after the validation of the candidate drugs.Skyhawk is eligible to receive a total of $1.8 billion in development and regulatory milestones.AndBusinessMilestone payment.

On April 2 this year,Ipsen has just$90 million in recent payments, with a total transaction amount reaching $900 million, secured the company's first ADC product:ROR1 ADC（STRO-003）。

It has only been 20 days,Ipsen reached two deals with a total value of $2.7 billion, which is close to its 2023 revenue of €3.128 billion (approximately $3.32 billion).

On April 22, NeuroSense and Genetika+ initiated a collaboration on AD medication. Starting with NeuroSense's ongoing Phase II AD clinical trial, the two parties will utilize Genetika+'s advanced technology to extract prefrontal cortex neurons from individual patient blood samples and quantify drug-induced neuroplasticity in vitro.

The drug for ALS in NeuroSense's pipeline has the fastest clinical progress.PrimeC, this drug is a combination of two old drugs (Celecoxib and Ciprofloxacin) Compound preparation.

Due to AD andAThere are common pathways between LS, such as neuroinflammation, protein aggregation, excitotoxicity, and oxidative stress. Therefore, NeuroSense has developed an AD drug based on PrimeC.

In February this year, additional positive data from the PARADIGM Phase 2b clinical trial of PrimeC for ALS showed that, compared to placebo, the drug significantly slowed disease progression and reduced the risk of ALS-related complications or death by up to 53%.

April 2On the 2nd, Lexeo Therapeutics announced a collaboration with Cornell University to accelerate the development of LX2006, a gene therapy under research for Friedreich ataxia cardiomyopathy.

According to the agreement, Lexeo has obtainedLX2006 Related Patents, the specific authorized amount is unknown.

FFriedreich's Ataxia Cardiomyopathy is an autosomal recessive, irreversible progressive disease, often leading to death due to heart failure or severe secondary neurodegenerative disorders.

As of the latest date, a total of 11 subjects have participated in the treatment. Among them, no treatment-related serious adverse events were observed in all patients with a treatment duration of up to 18 months, and the treatment was well tolerated.

Expected in mid-2024,Lexeo willRelease of Interim Readout Results for Multiple Doses in the Pooled Dataset。

Bayer Co.Lab Shanghai Officially Launches Recruitment for Resident Companies

Who Says CAR-T Doesn't Make Money?

Why Are Doctors Reluctant to Prescribe Generic Drugs?

Click to read the original text and learn more!